Fig. 2From: Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case seriesA diagram demonstrating the cytoreductive therapies used in the management of each patient. Each bar shows the time from point of diagnosis through to most recent follow-up that each therapy was used. Episodes of Cytopenia and Intolerance are recorded. HU = Hydroxycarbamide, IFN = Interferon, RUX = RuxolitinibBack to article page